• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525

Introduction to (S)-3-Amino-4-(3-methylphenyl)butyric Acid Hydrochloride (CAS No. 270062-92-5)

(S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride, identified by its CAS number 270062-92-5, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This chiral amino acid derivative has garnered considerable attention due to its potential applications in drug development and therapeutic interventions. The hydrochloride salt form enhances its solubility and stability, making it a valuable intermediate in synthetic chemistry and a candidate for further biological evaluation.

The molecular structure of (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride consists of a butyric acid backbone substituted with an amino group at the third carbon and a 3-methylphenyl group at the fourth carbon. This specific stereochemistry, denoted by the (S) configuration, is crucial for its biological activity. The presence of the aromatic ring and the amino acid moiety suggests potential interactions with biological targets, such as enzymes and receptors, which are pivotal in modulating various physiological processes.

Recent research has highlighted the importance of chiral amino acids in pharmaceutical development. The enantiomeric purity of (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride is essential for achieving the desired therapeutic effects while minimizing adverse reactions. Studies have demonstrated that the (S)-enantiomer exhibits distinct pharmacological properties compared to its (R)-counterpart, underscoring the significance of stereochemical control in drug design.

In the context of drug discovery, (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride has been explored as a building block for more complex molecules. Its structural features make it a versatile precursor for synthesizing peptidomimetics and other pharmacophores. For instance, modifications at the amino and carboxyl groups can lead to novel compounds with enhanced binding affinity and selectivity towards specific biological targets.

The hydrochloride salt form of this compound improves its handling and formulation properties. Hydrochlorides are commonly used in pharmaceuticals due to their high solubility in water, which facilitates oral administration and enhances bioavailability. This characteristic makes (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride an attractive candidate for developing oral medications targeting various diseases.

Current research initiatives are focusing on leveraging the structural attributes of (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride in the development of novel therapeutics. One area of interest is its potential role in modulating neurotransmitter systems. The compound's ability to interact with amino acid receptors suggests applications in treating neurological disorders such as depression, anxiety, and cognitive impairments. Preclinical studies have begun to explore its efficacy in animal models, providing preliminary evidence of its therapeutic potential.

Another promising application lies in its use as an intermediate in the synthesis of bioactive peptides. Peptides have gained prominence in medicine due to their specificity and efficacy in targeting disease-causing pathways. By incorporating (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride into peptide chains, researchers can fine-tune the pharmacokinetic properties and improve the stability of these molecules. This approach holds promise for developing next-generation peptide-based drugs with improved clinical outcomes.

The synthesis of chiral compounds like (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride often presents challenges due to the need for high enantiomeric purity. Advanced synthetic methodologies, such as asymmetric catalysis and enzymatic resolution, are being employed to achieve optimal yields and selectivity. These techniques not only enhance the efficiency of production but also contribute to sustainable chemical manufacturing practices.

Evaluation of the toxicological profile is a critical step before moving any compound into clinical trials. Preliminary toxicity studies on (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride have shown favorable results, indicating low systemic toxicity at relevant doses. However, comprehensive safety assessments are necessary to ensure its suitability for human use. Collaborative efforts between synthetic chemists, biologists, and clinicians are essential for translating laboratory findings into viable therapeutic options.

The future prospects of (S)-3-Amino-4-(3-methylphenyl)butyric acid hydrochloride are bright, with ongoing research aimed at expanding its applications across multiple therapeutic areas. As our understanding of biological systems continues to evolve, new opportunities will emerge for utilizing this compound as a key intermediate or lead molecule. The integration of computational modeling and high-throughput screening techniques will further accelerate the discovery process, bringing us closer to realizing its full potential.

• 26250-87-3((S)-3-Amino-4-phenylbutanoic acid)
• 15099-85-1(3-Amino-4-phenylbutanoic acid)
• 131270-08-1((R)-3-Amino-4-phenylbutanoic acid)
• 916198-97-5((4S)-4-amino-5-phenyl-pentanoic acid)
• 91247-38-0(3-Amino-5-phenylpentanoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)